Akagera Medicines Reports Positive First-in-Human Data for Single-Ascending-Dose of AKG-100, Advancing a Potentially Transformative Long-Acting Therapeutic for Drug-Resistant Tuberculosis

Phase 1positiveAKG-100Positive

AI Analysis

Summary

Akagera Medicines reported positive Phase 1 single-ascending-dose data for AKG-100, showing favorable safety and tolerability across all doses with pharmacokinetics supporting infrequent dosing potential for drug-resistant tuberculosis. The company is advancing to a multiple-ascending-dose study.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

Favorable safety and tolerability across all dose levels; pharmacokinetics support potential for infrequent dosing

Importance:6/10

Sentiment:

0.80

tuberculosisPhase 1first-in-humanlong-actingpharmacokineticssafetytolerability

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on July 20, 2026 2:00 PM

Read Original